1. Home
  2. CABA vs PLBY Comparison

CABA vs PLBY Comparison

Compare CABA & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.39

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.88

Market Cap

232.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABA
PLBY
Founded
2017
1953
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
227.2M
232.8M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CABA
PLBY
Price
$2.39
$1.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$13.50
$3.00
AVG Volume (30 Days)
2.2M
1.4M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$119,510,000.00
Revenue This Year
N/A
$4.97
Revenue Next Year
N/A
$8.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.90
52 Week High
$3.67
$2.53

Technical Indicators

Market Signals
Indicator
CABA
PLBY
Relative Strength Index (RSI) 48.61 49.81
Support Level $2.32 $1.72
Resistance Level $2.48 $1.97
Average True Range (ATR) 0.14 0.19
MACD -0.00 -0.05
Stochastic Oscillator 17.50 14.81

Price Performance

Historical Comparison
CABA
PLBY

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

Share on Social Networks: